all trans retinoic acid

DRUG7 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), St. Petersburg State Pavlov Medical University, Icahn School of Medicine at Mount Sinai, Peking University People's Hospital, The First Affiliated Hospital of Soochow University

Conditions

AMLChronic Obstructive Pulmonary DiseaseColorectal CancerEffect of DrugEmphysemaHematologic CancerImmune ThrombocytopeniaLung Diseases

Early Phase 1

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Active, not recruitingNCT05482451

China Medical University HospitalEffect of Drug

Start: 2021-03-01End: 2025-02-28Updated: 2024-08-21

Phase 1

Nivolumab With Chemotherapy in Refractory MDS

TerminatedNCT03259516

St. Petersburg State Pavlov Medical UniversityMyelodysplastic Syndromes

Start: 2017-05-25End: 2018-12-25Updated: 2019-04-05

Phase 2

Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)

CompletedNCT00000621

National Heart, Lung, and Blood Institute (NHLBI)Chronic Obstructive Pulmonary Disease, Emphysema, Lung Diseases +1

Start: 1999-09-30End: 2004-12-31Updated: 2008-01-16

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

CompletedNCT03572387

Icahn School of Medicine at Mount SinaiProstate Cancer, Prostate Neoplasms, Prostatic Neoplasms

Start: 2018-08-20End: 2022-07-08Updated: 2024-04-30

A Study of ATRA in the Treatment of ITP

Peking University People's HospitalImmune Thrombocytopenia

Start: 2020-11-30End: 2021-10-31Target: 80Updated: 2020-11-05

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

The First Affiliated Hospital of Soochow UniversityAML, Hematologic Cancer, MDS +1

Start: 2021-05-01End: 2023-05-01Target: 180Updated: 2022-01-03

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Active, not recruitingNCT05999812

University of Texas Southwestern Medical CenterColorectal Cancer

Start: 2023-12-19End: 2028-10-01Updated: 2025-05-25

Related Papers

Safety and tolerability of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer.

Journal of Clinical Oncology2026-01-10

Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer.

Journal of Clinical Oncology2025-01-271 citations

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial

Frontiers in Immunology2019-05-3158 citations